@franckdrtourte
PhD in virology Associate professeur in @UVE lab (Marseille, France). Holder of the new chair: Antiviral strategies for emergence in the south @IRD Head of the PCVMT platform ( sub-entity of MaSC) dedicated to antiviral screening with replicating viruses.
How Can Pharmacology Help Us Overcome the Challenges of Drug Repositioning as Antivirals to Treat Emerging Pathogens? The Example of Covid‐19
Revue entre Paris, Dijon, Marseille avec @franckdrtourte.bsky.social et le juteux @nathanpsmad.bsky.social
ascpt.onlinelibrary.wiley.com/doi/10.1111/...
Exciting news! Our latest study on SARS-CoV-2 variants and therapeutic strategies is now out in Scientific Reports
Huge thanks to the Emergen_Biovar team for their contributions to this work @franckdrtourte.bsky.social @pf-ccb.bsky.social
Full paper here: www.nature.com/articles/s41...
#virology
Yes on suit ça de près aussi 😁
While not a replacement for standard antiviral screening, this 3D model offers valuable insights into viral replication, pathogenicity, and host-pathogen interactions.
Our research findings:
RVFV and PIRV replicated in the liver spheroids; AHFV and YFV did not.
Broad-spectrum antivirals (favipiravir, nitazoxanide, ribavirin, galidesivir) showed activity, though higher doses were often needed versus traditional 2D models.
Haemorrhagic fever viruses remain a major global health threat—highly lethal, with limited therapeutic options. In our recent study, we explored a 3D human liver spheroid model to evaluate its potential for antiviral assessment against 4 BSL-3 viruses: AHFV, YFV, PIRV, RVFV.
Just published in Antiviral research!
3D Liver Spheroids in the Fight Against Haemorrhagic Fever Viruses
t.co/FuxQ76acrg
@ird-fr.bsky.social @univ-amu.fr @insermpacacorse.bsky.social
On a des antiviraux efficaces: paxlovid ( Nirmatrelvir) et xocova ( ensitrelvir) on sait comment faire un vaccin ou des anticorps thérapeutiques rapidement.
On est entouré de virus à la capacité zoonotique et celui là se rajoute juste à la longue liste mais tkt a l UVE on est là pour ça 😉
Oui c’est uniquement l’entrée mais d’autre facteurs rentrent en ligne de compte pour un changement d’hôte et une zoonose( par exemple la capacité du virus à échapper à la réponse immune). De plus avec le recul un coronavirus est moins inquiétant que d’autres familles virales 1/2
Moreover, pharmacokinetic modeling suggests promising druggability for these compounds.
These results position OM1260 and HR-568 as strong candidates for further development, potentially paving the way for the first curative treatments for enteroviral infections.
Docking studies provided insights into their structure-activity relationships, while time-of-drug addition assays revealed that these inhibitors act early in the viral replication cycle.
This led to the discovery of two promising broad-spectrum inhibitors, OM1260 and HR-568.
Both inhibitors show micromolar activity against multiple enterovirus types (EV-A71, E30, and CVA24), with EC50 values ranging from 0.4 μM to 4.38 μM, depending on the virus strain and cell line.
Our consortium has made an exciting step forward in the fight against these viruses. After developing initial EV-A71 inhibitors, we optimized their structure through iterative chemical modifications to enhance their activity and broaden their spectrum.
Despite their significant impact, there are currently no commercial curative treatments available.
🔬 New Research Breakthrough: Broad-Spectrum Inhibitors for Enteroviruses🦠Enteroviruses (EV) are a diverse group of viruses that can cause a range of illnesses, from mild fever to severe neurological complications.
Read more about our findings in the preprint! 📖
www.biorxiv.org/content/10.1...
Our research underscores the growing importance of advanced 3D models in virology and drug development. This tool could help accelerate the identification of new therapies for HFVs and improve our understanding of their mechanisms.
While this model offers valuable insights, it’s not a replacement for standard selection steps in antiviral drug development but could play a key role in understanding viral pathogenicity and host-pathogen interactions.
Key findings :
RVFV and PIRV were able to replicate in the spheroids, while the orthoflaviviruses did not show replication.
Antiviral compounds like favipiravir, nitazoxanide, ribavirin, and galidesivir demonstrated activity, though higher doses were required in 3D models compared to 2D cultures.
Our latest study explores the use of a 96-well liver spheroid model composed of human primary cells to assess the antiviral activity of key compounds against four BSL-3 HFVs: Alkhumra haemorrhagic fever virus (AHFV), yellow fever virus (YFV), Pirital virus (PIRV), and Rift Valley fever virus (RVFV).
🚨 New Insights on Hemorrhagic Fever Viruses & 3D Cell Culture Models 🦠
In the ongoing battle against hemorrhagic fever viruses (HFVs), the development of effective antiviral strategies remains a critical challenge.
From Rogue virologist
www.nature.com/articles/s41...
The main paper of my PhD thesis
Due to the words limitation i will make it short but thanks to @franckdrtourte.bsky.social , Dr. Suzanne Kaptein, @neytsjohan.bsky.social, Christian Alfano, Carla Gomes da Silva, Ivan Gladwyn-ng, Emily Slowikowski and Prof Marques
🤚please
Merci
👋🏻
👋🏻
C’est énorme! Faut faire une grosse fiesta!
C’est super cool de pouvoir tracer son histoire aussi loin!
